Social media

There is great excitement following the announcements by the FDA and EMA around streamlining the biosimilar trial process. They promise to reduce the burden on developers and therefore increase the number of more afford...

Do you know the difference between decision trees and random forests? Learn about AI models for SaMDs in our new whitepaper. Download it now to learn best practices for model and data selection. https://ow.ly/nI8g50XAzbq

For medical device developers selecting the right AI model and data is crucial to capitalise on this powerful technology. Our new whitepaper explains best practices for AI-enabled devices. Learn about AI models, datase...

Yao Zhong's career in clinical development spans two decades and multiple leadership roles across the industry. When the opportunity came to return to ICON and lead our newly integrated China business, he recognised the ...

Zhong Yao's career in clinical development spans two decades and multiple leadership roles across the industry. When the opportunity came to return to ICON and lead our newly integrated China business, he recognised the ...

In a fast-moving market like healthcare, speed matters. Metys®, from Symphony Health, an ICON plc company, delivers weekly insights up to 3 days faster than other platforms – so you can respond to competitive shifts wi...

In a fast-moving market like healthcare, speed matters. Metys®, from Symphony Health, an ICON plc company, delivers weekly insights up to 3 days faster than other platforms – so you can respond to competitive shifts wi...

How do you go from a meaningful aspect of health to a validated endpoint? Download our whitepaper for a step-by-step guide on a structured approach to deploying digital endpoints: 1. Define the Concept of Interest 2. Id...

Sites are the operational heart of clinical trials. ICON’s site-centric approach turns bottlenecks into breakthroughs. Read the whitepaper: https://ow.ly/3w8u50XB70W

AI and predictive analytics are transforming clinical data risk management. CRAs are essential to successful trial. Read more on how tech empowers, not replaces, the CRA. Read the ACT article: https://ow.ly/ESvn50XB6TW

AI and predictive analytics are transforming clinical data risk management. CRAs are essential to successful trial. Read more on how tech empowers, not replaces, the CRA. Read the ACT article: https://ow.ly/3cSa50XB6TY

Keep up to date on the most recent regulatory changes in the world of pharma, biotech and medical device clinical trials with ICON’s Regulatory Intelligence Newsletter. Join thousands of subscribers who have discovered...